Advertisement
New Zealand markets closed

  • NZX 50

    11,938.08
    +64.04 (+0.54%)
     

  • NZD/USD

    0.6012
    +0.0049 (+0.83%)
     

  • NZD/EUR

    0.5579
    +0.0023 (+0.42%)
     

  • ALL ORDS

    7,897.50
    +48.10 (+0.61%)
     

  • ASX 200

    7,629.00
    +42.00 (+0.55%)
     

  • OIL

    77.99
    -0.96 (-1.22%)
     

  • GOLD

    2,310.10
    +0.50 (+0.02%)
     

  • NASDAQ

    17,890.79
    +349.25 (+1.99%)
     

  • FTSE

    8,213.49
    +41.34 (+0.51%)
     

  • Dow Jones

    38,675.68
    +450.02 (+1.18%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • Hang Seng

    18,475.92
    +268.79 (+1.48%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • NZD/JPY

    91.9390
    +0.3640 (+0.40%)
     

Merck raises 2024 guidance on cancer drug demand

Seana Smith and Brad Smith

Shares of Merck & Company (MRK) are trading higher early Thursday after the pharmaceutical giant posted robust sales results in the first quarter, leading the pharmaceutical giant to raise its 2024 outlook. The company's performance was driven by strong demand for its cancer drug Keytruda.

Yahoo Finance's Anjalee Khemlani breaks down the details.

For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance.

This post was written by Angel Smith